GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » EV-to-EBIT

ZELTIQ Aesthetics (ZELTIQ Aesthetics) EV-to-EBIT : 169.96 (As of Apr. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ZELTIQ Aesthetics's Enterprise Value is $2,247.5 Mil. ZELTIQ Aesthetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was $13.2 Mil. Therefore, ZELTIQ Aesthetics's EV-to-EBIT for today is 169.96.

The historical rank and industry rank for ZELTIQ Aesthetics's EV-to-EBIT or its related term are showing as below:

ZLTQ's EV-to-EBIT is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 19.675
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ZELTIQ Aesthetics's Enterprise Value for the quarter that ended in Dec. 2016 was $1,691.6 Mil. ZELTIQ Aesthetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was $13.2 Mil. ZELTIQ Aesthetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 0.78%.


ZELTIQ Aesthetics EV-to-EBIT Historical Data

The historical data trend for ZELTIQ Aesthetics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics EV-to-EBIT Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBIT
Get a 7-Day Free Trial -4.01 -33.89 479.93 289.91 127.93

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 289.91 -178.24 -94.06 -1,216.87 127.93

Competitive Comparison of ZELTIQ Aesthetics's EV-to-EBIT

For the Medical Devices subindustry, ZELTIQ Aesthetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZELTIQ Aesthetics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ZELTIQ Aesthetics's EV-to-EBIT falls into.



ZELTIQ Aesthetics EV-to-EBIT Calculation

ZELTIQ Aesthetics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2247.490/13.224
=169.96

ZELTIQ Aesthetics's current Enterprise Value is $2,247.5 Mil.
ZELTIQ Aesthetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZELTIQ Aesthetics  (NAS:ZLTQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ZELTIQ Aesthetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2016 ) =EBIT / Enterprise Value (Q: Dec. 2016 )
=13.224/1691.5628
=0.78 %

ZELTIQ Aesthetics's Enterprise Value for the quarter that ended in Dec. 2016 was $1,691.6 Mil.
ZELTIQ Aesthetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZELTIQ Aesthetics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines